Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -45% Improvement Relative Risk c19hcq.org Sarfaraz et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 186 patients in Pakistan Higher mortality with HCQ (not stat. sig., p=0.068) Sarfaraz et al., medRxiv, doi:10.1101/2020.12.28.20248920 Favors HCQ Favors control
Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan
Sarfaraz et al., medRxiv, doi:10.1101/2020.12.28.20248920 (Preprint)
Sarfaraz et al., Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan, medRxiv, doi:10.1101/2020.12.28.20248920 (Preprint)
Jan 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 186 hospitalized patients in Pakistan showing unadjusted HCQ mortality RR 1.45, p = 0.07. Confounding by indication is likely. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely; significant unadjusted confounding possible; unadjusted results with no group details.
risk of death, 45.0% higher, RR 1.45, p = 0.07, treatment 40 of 94 (42.6%), control 27 of 92 (29.3%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sarfaraz et al., 2 Jan 2021, retrospective, Pakistan, preprint, 7 authors, average treatment delay 7.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248920; this version posted January 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title: Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan Samreen Sarfaraz1, Quratulain Shaikh2, Syed Ghazanfar Saleem3, Anum Rahim4 Fivzia Farooq Herekar5, Samina Junejo6, Aneela Hussain7 1-Samreen Sarfaraz, FRCP (Glasg) Infectious Disease Department, The Indus Hospital, Karachi 2- Quratulain Shaikh, FCPS, MSc Indus Hospital Research Centre, The Indus Hospital, Karachi 3-Syed Ghazanfar Saleem, FCPS Emergency Department, The Indus Hospital, Karachi 4-Anum Rahim, MBBS, MSc Indus Hospital Research Centre, The Indus Hospital Karachi 5- Fivzia Farooq Herekar, FCPS Internal Medicine Department, The Indus Hospital, Karachi 6-Samina Junejo, FCPS Paediatric infectious Diseases, The Indus Hospital, Karachi 7-Aneela Hussain, FCPS Infectious Disease Department, The Indus Hospital, Karachi Corresponding Author: Samreen Sarfaraz, Email: samreen.sarfaraz@tih.org.pk samreen2002@gmail.com Office Tel: +92(21)35112709-17, Office Fax no.: +92(21)35112718 Cell no.:+923232688200 Postal Address: The Indus Hospital, Plot C-76, Sector 3 1/5, Opposite Korangi Crossing, Karachi -75190. Word Count of summary: 199 Word count of the text: 2877 References: 40 Tables: 4 Figures: 2 Summary NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248920; this version posted January 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . A prospective cohort study was conducted at the Indus Hospital Karachi, Pakistan between March and June 2020 to describe the determinants of mortality among hospitalized COVID-19 patients. 186 adult patients were enrolled and all-cause mortality was found to be 36% (67/186). Those who died were older and more likely to be males (p<0.05). Temperature and respiratory rate were higher among non-survivors while Oxygen saturation was lower (p<0.05). Serum CRP, D-dimer and IL-6 were higher while SpO2 was lower on admission among non-survivors (p<0.05). Non-survivors had higher SOFA and CURB-65 scores while thrombocytopenia, lymphopenia and severe ARDS was more prevalent among them (p<0.05). Use of non-invasive ventilation in emergency room, ICU admission and invasive ventilation were associated with mortality in our cohort (p<0.05). Length of hospital stay and days of intubation were longer in non-survivors (p<0.05). Use of azithromycin, hydroxychloroquine, steroids, tocilizumab, antibiotics, IVIG or anticoagulation showed no mortality benefit (p>0.05). Multivariable logistic regression showed that age > 60 years, oxygen saturation <93% on admission, pro-calcitonin > 2 ng/ml, unit rise in temperature and SOFA score, ICU admission and sepsis during hospital stay were associated with higher odds of mortality. Larger prospective studies are needed to further strengthen these findings. Key Findings 1. Age greater than 60 years is..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit